Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years~2. Both genders~3. Diagnosis of non-m3 AML by the WHO 2016 diagnostic criteria~4. Patients eligible and not eligible for transplant~5. AML secondary to treatment or associated to myelodisplasia~Exclusion Criteria:~1. AML with PML/RAR-alfa translocation t(15;17)~2. Central nervous system involvement~3. Poor functional status (ECOG\>2)~4. Organic dysfunction (Marshall score ≥2)~5. Active infection~6. Use of other CYP3A4 inhibitors~7. Pregnancy~8. GFR \<30 ml/min/1.72m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low-dose Ventoclax and oral itraconazol plus subcutaneous Azacitdine (Type: EXPERIMENTAL): Patients will recieve Low-dose Venetoclax at a dose of 100mg/day por 21 days, oral itraconazol 100mg every 12 hours, and subcutaneous Azacitidine 75mg/m2 (maximun dose 100mg) daily for seven days. Each cycle duration is 21 days and patients will recieve a maximun of two cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).